Prevacid OTC switch gets $200 million launch effort

Share this article:
Prevacid OTC switch gets $200 million launch effort
Prevacid OTC switch gets $200 million launch effort
Novartis Consumer Health launched OTC Prevacid with a $200 million marketing campaign featuring the tagline: “When you've had it with heartburn.”

Prevacid 24HR, as the OTC version is known, still bears the pink and teal colors of its prescription predecessor. Ads focusing on sufferers' “moment of decision”—in the spot pictured, a first date with Mr. Right marred by heartburn -- are by Deutsch. Tribal DDB is handling digital and social media, including branded (www.Prevacid24HR.com) and unbranded (www.heartburnactionplan.com) sites, and Ruder Finn is handling PR for the brand.

The drug will compete with Procter & Gamble's OTC Prilosec as well as prescription drugs like AstraZeneca's Nexium and Eisai/PriCara drug AcipHex, among others.

P&G retaliated with its announcement that it is partnering with football great John Madden for the Madden Most Valuable Protectors Award, recognizing top offensive linemen. The award will be presented during the week of Super Bowl XLIV in Miami.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...